User login
Key clinical point: Phototherapy with narrowband (NB) ultraviolet type B (UV-B) light showed high and long-lasting efficacy in atopic dermatitis (AD) with patients with facial involvement and adverse events (AE) responding poorly to the treatment.
Major finding: Overall, 55.4% patients achieved Investigator’s Global Assessment score of 0 and 1 with an overall median response duration of 12 months. Facial involvement (odds ratio [OR] 2.743; P < .001), adverse events (OR 2.366; P = .015), and lower number of treatments (OR 1.017; P = .089) were related with poor response.
Study details: Findings are from a retrospective cohort study of 390 patients with moderate-to-severe AD who were treated with NB-UV-B therapy and followed up for at least 3 years after completing therapy.
Disclosures: This study did not report any funding. The authors declared no conflict of interests.
Source: Ben Mordehai Y et al. Dermatitis. 2021 (Nov 27). Doi: 10.1097/DER.0000000000000810.
Key clinical point: Phototherapy with narrowband (NB) ultraviolet type B (UV-B) light showed high and long-lasting efficacy in atopic dermatitis (AD) with patients with facial involvement and adverse events (AE) responding poorly to the treatment.
Major finding: Overall, 55.4% patients achieved Investigator’s Global Assessment score of 0 and 1 with an overall median response duration of 12 months. Facial involvement (odds ratio [OR] 2.743; P < .001), adverse events (OR 2.366; P = .015), and lower number of treatments (OR 1.017; P = .089) were related with poor response.
Study details: Findings are from a retrospective cohort study of 390 patients with moderate-to-severe AD who were treated with NB-UV-B therapy and followed up for at least 3 years after completing therapy.
Disclosures: This study did not report any funding. The authors declared no conflict of interests.
Source: Ben Mordehai Y et al. Dermatitis. 2021 (Nov 27). Doi: 10.1097/DER.0000000000000810.
Key clinical point: Phototherapy with narrowband (NB) ultraviolet type B (UV-B) light showed high and long-lasting efficacy in atopic dermatitis (AD) with patients with facial involvement and adverse events (AE) responding poorly to the treatment.
Major finding: Overall, 55.4% patients achieved Investigator’s Global Assessment score of 0 and 1 with an overall median response duration of 12 months. Facial involvement (odds ratio [OR] 2.743; P < .001), adverse events (OR 2.366; P = .015), and lower number of treatments (OR 1.017; P = .089) were related with poor response.
Study details: Findings are from a retrospective cohort study of 390 patients with moderate-to-severe AD who were treated with NB-UV-B therapy and followed up for at least 3 years after completing therapy.
Disclosures: This study did not report any funding. The authors declared no conflict of interests.
Source: Ben Mordehai Y et al. Dermatitis. 2021 (Nov 27). Doi: 10.1097/DER.0000000000000810.